Search results

Altasciences determines the suitability of nano milling for a client’s highly active compound with very poor aqueous solubility and less than desirable bioavailability.

A leading developer of novel cancer therapeutics was experiencing persistent manufacturing process issues. Our engineers were able to diagnose and solve two problems.

Issue 33 of The Altascientist investigates the benefits of integrated drug development solutions for the ever-increasing world of CNS therapeutics.

Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.

Can the drug development industry change for the better? We dive into the obstacles and inefficiencies of the traditional outsourcing paradigm, and discuss how Altasciences offers an alternative to help sponsors safely accelerate their R&D.